In:
International Journal of Cancer, Wiley, Vol. 137, No. 1 ( 2015-07), p. 243-250
Abstract:
What's new? Oxaliplatin is a key component in adjuvant and palliative therapy for colorectal cancer, but its use is limited by the development of neuropathy, which typically is unresponsive to treatment. Following on previous work in which protein kinase C (PKC) activation was implicated in oxaliplatin‐induced neuropathy, the present report suggests that PKC and MEK inhibitors may be able to block the neuropathic side effects. Inhibition was effected in the lumbar spinal cords of mice, via the PKC/ERK/c‐Fos pathway. PKC and MEK inhibitors were also found to act synergistically to potentiate the tumor suppressive effects of oxaliplatin.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink